Levosimendans Pharmacokinetics in Intensive Care Patients. An Observational Study.

Launched by KAROLINSKA INSTITUTET · Oct 12, 2021

Keywords

ClinConnect Summary

This clinical trial is looking at how a medication called levosimendan behaves in the body of intensive care patients. Specifically, it studies how the body absorbs, distributes, and eliminates this drug, along with its breakdown products, in patients who have normal kidney function, reduced kidney function, or those on dialysis. The aim is to gather important information that can help doctors understand the best way to use levosimendan in patients who need it most, especially those with conditions affecting their kidneys.

To be eligible for this study, patients must be adults in intensive care who their doctors believe need treatment with levosimendan. Unfortunately, younger patients (under 18), pregnant individuals, and those receiving intermittent hemodialysis cannot participate. If you or a loved one is considering joining this trial, you can expect to undergo routine assessments while receiving care in the intensive care unit. This study is currently recruiting participants, and your involvement could help advance our understanding of how this medication works for critically ill patients.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • ° Adult Intensive care patients in whom treating physicians have judged to be in need of Levosimendan treatment.
• Exclusion Criteria:
• • Patient \<18 years of age
• • Pregnancy
• • Patients receiving Intermittent hemodialysis